## Contents

### Highlights of This Issue  5831

#### SPECIAL FEATURES

**Editorial**

5833  
*Gauging Progress in a Decades-Old Fight*

Jesse Potash and Kenneth C. Anderson

---

**CCR Translations**

5834  
*Model T Muscle CARs Can Treat Brain Tumors*

Laura A. Johnson  
*See article p. 5949*

---

**CCR New Strategies**

5837  
*New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents*

Katherine A. Janeway and Robert G. Mak

---

**CCR Perspectives in Drug Approval**

5845  
*U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma*


---

**Molecular Pathways**

5850  
*Molecular Pathways: Tumor Cells Co-opt the Brain-Specific Metabolism Gene CPT1C to Promote Survival*

Patrick T. Reilly and Tak W. Mak

---

### Review  5856

The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer

Brian M. Slomovitz and Robert L. Coleman

---

### HUMAN CANCER BIOLOGY  5865

Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis

Carolyn D. Hurst, Fiona M. Platt, Claire F. Taylor, and Margaret A. Knowles

---

Functional, Genetic, and Epigenetic Aspects of Base and Nucleotide Excision Repair in Colorectal Carcinomas


---

Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells

Shahriar Koochekpour, Sanjina Majumdar, Gissou Azabafzari, Kristopher Allwood, Ray Scineaux, Dhatxhayini Subramani, Charles Manhardt, Giovanni D. Lorusso, Stacey S. Willard, Hillary Thompson, Mojgan Shourideh, Katayoon Rezaei, Oliver Sartor, James L. Mohler, and Robert L. Vessella

---

Expression of Serotonin Receptors in Human Hepatocellular Cancer

Christopher Soll, Marc-Oliver Rieker, Christian Eugen Oberkofler, Claus Hellerbrand, Peter J. Wild, Michelle L. DeOliveira, and Pierre-Alain Clavien
# CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5911</td>
<td>Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo</td>
<td>Fiona Simpkins, Pedro Hevia-Paez, Jun Sun, Wendy Ullmer, Candace A. Gilbert, Thiago da Silva, Ali Pedram, Ellis R. Levin, Islădinha M. Reis, Brian Rabinovich, Diana Azzam, Xiang-Xi Xu, Tan A. Ince, Ji-Yeon Yang, Roel G.W. Verhaak, Yiling Lu, Gordon B. Mills, and Joyce M. Slingerland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5983</td>
<td>Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer</td>
<td>Dharami Madhavan, Manuela Zucknick, Markus Wallwiener, Katarina Cuk, Caroline Modugno, Martina Scharpf, Sarah Schott, Jörg Heil, Andrey Turchinovich, Rongxi Yang, Axel Benner, Sabine Riedt, Andreas Trumpp, Christof Sohn, Klaus Pantel, Andreas Schneeweiss, and Barbara Burwinkel</td>
</tr>
</tbody>
</table>

# CANCER THERAPY: CLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6011</td>
<td>A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report</td>
<td>Brigitte C. Widemann, Aeilkang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Balis, and Susan M. Blaney</td>
</tr>
</tbody>
</table>

# IMAGING, DIAGNOSIS, PROGNOSIS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5972</td>
<td>Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer</td>
<td>Dharami Madhavan, Manuela Zucknick, Markus Wallwiener, Katarina Cuk, Caroline Modugno, Martina Scharpf, Sarah Schott, Jörg Heil, Andrey Turchinovich, Rongxi Yang, Axel Benner, Sabine Riedt, Andreas Trumpp, Christof Sohn, Klaus Pantel, Andreas Schneeweiss, and Barbara Burwinkel</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

# CANCER THERAPY: CLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6011</td>
<td>A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report</td>
<td>Brigitte C. Widemann, Aeilkang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Balis, and Susan M. Blaney</td>
</tr>
</tbody>
</table>

---

Clinical Cancer Research
Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
Yan Xin, Jessica L. Jenny Wu, Rashell Kinard, Colin D. Weekes, Amanda Patnaik, Patricia LoRusso, Rainer Brachmann, Raymond K. Tong, Yibing Yan, Ryan Watts, Shuang Bai, and Priti S. Hegde

Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)
Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, Lukas Bubendorf, Rolf Jaggi, Daniel C. Betticher, Peter Brauchli, Denise Cotting, Cornelia Droeger, Ralph Winterhalder, Daniele Siciliano, Dominik R. Berthold, Miklos Pless, Ralph Schiess, Roger von Moos, and Silke Gillessen; for the Swiss Group for Clinical Cancer Research (SAKK)

PEDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine
Shigeyuki Matsui, Richard Simon, Pingping Qu, John D. Shaughnessy Jr, Bart Barlogie, and John Crowley

LETTERS TO THE EDITOR

Spleen Cells from Young Donors Eradicate Large Tumors—Letter
Laszlo Radvanyi

Spleen Cells from Young Donors Eradicate Large Tumors—Response
Donald A. Rowley, Karin Schreiber, and Hans Schreiber

Bioluminescence Imaging of Prenylation Inhibition—Letter
Philippe Clezardin

Bioluminescence Imaging of Prenylation Inhibition—Response
Kendall J. Blumer, Katherine Weilbaecher, and David Piwnica-Worms

CORRECTION

Correction: The Use of Quantitative Real-Time Reverse-Transcriptase PCR for 5’ and 3’ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
ABOUT THE COVER

Serotonin receptors are expressed in the liver and human hepatocellular cancer (HCC). The cover shows the immunohistochemical staining of the serotonin receptor 1B (HTR1B) in a specimen of human HCC. In a subset of tumors, the expression of HTR1B was significantly increased compared with corresponding nontumor liver tissue of the same patient. The expression of the receptor correlated with a higher proliferation rate and tumor size, suggesting an involvement of serotonin receptors in tumor growth of human HCC. For details, see the article by Soll and colleagues on page 5902 of this issue.
Clinical Cancer Research

18 (21)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/18/21

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.